Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 28;17(1):226.
doi: 10.1186/s12885-017-3208-6.

Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?

A Oberguggenberger  1 , V Meraner  1 , M Sztankay  1 , B Beer  2 , G Weigel  3 , H Oberacher  2 , G Kemmler  1 , T Czech  4 , B Holzner  1 , L Wildt  5 , B Sperner-Unterweger  1 , M Daniaux  6 , M Hubalek  7
Affiliations

Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?

A Oberguggenberger et al. BMC Cancer. .

Abstract

Background: BMI has been suggested to impact on estrogenic activity in patients receiving anastrozole resulting in a reduced treatment efficacy in obese women. Current evidence in this regard is controversially discussed. Since estradiol is inversely correlated with gonadotropins it can be assumed that an impact of BMI is also reflected by gonadotropin plasma concentrations. We aim at investigating the impact of BMI on the hormonal state of breast cancer (BC) patients receiving anastrozole indicated by LH, FSH and SHBG as well as estradiol.

Methods: We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal, early stage breast cancer patients receiving upfront anastrozole within routine after care. Gonadotropin plasma concentrations were derived from the routine laboratory examination report. A liquid chromatography tandem mass spectrometry method was used for the measurement of anastrozole serum concentrations. BMI was assessed within the routine after-care check-up.

Results: The overall sample comprised 135 BC patients with a mean age of 65.3 years. BMI was significantly correlated with LH, FSH and SHBG. This association was neither influenced by age nor by anastrozole serum concentrations according to the regression model. Despite aromatase inhibition 12% of patients had detectable estrogen levels in routine quantification.

Conclusion: Obese women have an altered hormonal situation compared to normally weight women under the same dose of anastrozole. Our study findings are a further indicator for the relevance of BMI in regard of anastrozole metabolism and possible estrogenic activity indicated by gonadotropin plasma level.

Keywords: Aromatase inhibitor; Body mass index; Breast cancer; Estradiol; Gonadotropins.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Association of BMI with gonadotropins (LH, FSH) and SHBG (n = 135) determined by use of Spearman Rank Correlation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ingle JN. Current status of adjuvant endocrine therapy for breast cancer. Clin Cancer Res. 2001;7(12 Suppl):4392s–4396s. - PubMed
    1. Rosner B, Glynn RJ, Tamimi RM, Chen WY, Colditz GA, Willett WC, Hankinson SE. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013;178(2):296–308. doi: 10.1093/aje/kws457. - DOI - PMC - PubMed
    1. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29(19):2653–2659. doi: 10.1200/JCO.2010.33.2585. - DOI - PubMed
    1. Ewertz M, Jensen MB, Gunnarsdóttir K, Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29(1):25–31. doi: 10.1200/JCO.2010.29.7614. - DOI - PubMed
    1. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–3415. doi: 10.1200/JCO.2009.27.2021. - DOI - PubMed